02113nas a2200349 4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653001000111653002100121653001100142653001100153653000900164653001600173653004500189653002700234653002600261653002500287100001500312700001800327700001100345700001100356700001100367245006800378300000900446490000700455520128700462022001401749 2004 d c2004 Feb10aAdolescent10aAdult10aAged10aAged, 80 and over10aChild10aChild, Preschool10aFemale10aHumans10aMale10aMiddle Aged10aMycobacterium Infections, Nontuberculous10aMycobacterium ulcerans10aRetrospective Studies10aSkin Transplantation1 aOuattara D1 aMeningaud J P1 aKaba L1 aSica A1 aAsse H00a[Treatment of Buruli ulcer desease by excision and skin graft]. a11-60 v493 a

INTRODUCTION: Buruli ulcer is the most common mycobacteria disease after leprosy and tuberculosis. The purpose of our study is to make our contribution to the surgical treatment of Buruli ulcer and to asses our results.

METHOD: One hundred eighteen patients presenting progressive Buruli ulcers were operated on. The surgical procedure included excisions for necrotic lesions and grafts for clean wounds. The results were estimated on the time of hospitalization and appearance of complications.

RESULTS: Seventy-three patients (62%) were subjected to excision followed by thin skin grafts and 35 patients (30%) were subjected to grafts only. The number of excision times varies from 1 to 7 per patient and from 1 to 4 for the skin grafts. All our patients heal within a period of 120 days with extremes going from 14 to 265 days. We deplored 26 complications (22%): eight new focus, seven infectious complications, six recurrences, five stiffnesses and ankyloses.

CONCLUSION: The treatment of Buruli ulcer by excision and grafts is efficient but does not prevent recurrences and new focus from happening and for their prevention, it is necessary to discover pharmaceutical molecules that are efficient on Mycobacterium ulcerans.

a0294-1260